# **Title Page**

# **Running Title: glucocorticoids for COVID-19**

Effectiveness and Safety of Glucocorticoids to Treat COVID-19: A Rapid Review and Meta-Analysis

Shuya Lu<sup>1,2,4\*</sup>, Qi Zhou<sup>3,4\*</sup>, Liping Huang<sup>5,6,7\*</sup>, Qianling Shi<sup>3,4</sup>, Siya Zhao<sup>8</sup>, Zijun Wang<sup>4</sup>, Weiguo Li<sup>5,6,7</sup>, Yuyi Tang<sup>5,6,7</sup>, Yanfang Ma<sup>4</sup>, Xufei Luo<sup>4,8</sup>, Toshio Fukuoka<sup>9,10</sup>, Hyeong Sik Ahn<sup>11,12</sup>, Myeong Soo Lee<sup>13,14</sup>, Zhengxiu Luo<sup>5,6,7</sup>, Enmei Liu<sup>5,6,7</sup>, Yaolong Chen<sup>4,15,16,17</sup>, Chenyan Zhou<sup>1,2#</sup>, Donghong Peng<sup>5,6,7#</sup>; on behalf of COVID-19 evidence and recommendations working group

- Department of Pediatric, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu 611731, China
- Chinese Academy of Sciences Sichuan Translational Medicine Research Hospital, Chengdu 610072, China
- The First School of Clinical Medicine, Lanzhou University, Lanzhou 730000, China
- Evidence-based Medicine Center, School of Basic Medical Sciences, Lanzhou University, Lanzhou 730000, China
- Department of Respiratory Medicine, Children's Hospital of Chongqing Medical University, Chongqing 400014, China
- National Clinical Research Center for Child Health and Diseases, Ministry of Education Key Laboratory of Child Development and Disorders, China

International Science and Technology Cooperation Base of Child Development and Critical Disorders, Children's Hospital of Chongqing Medical University, Chongqing 400014, China

- 7. Chongqing Key Laboratory of Pediatrics, Chongqing 400014, China
- 8. School of Public Health, Lanzhou University, Lanzhou 730000, China
- Emergency and Critical Care Center, the Department of General Medicine, Department of Research and Medical Education at Kurashiki Central Hospital, Japan
- 10. Advisory Committee in Cochrane Japan, Japan
- Department of Preventive Medicine, Korea University College of Medicine, Seoul, Korea
- 12. Korea Cochrane Centre, Korea
- 13. Korea Institute of Oriental Medicine, Daejeon, Korea
- 14. University of Science and Technology, Daejeon, Korea
- 15. Lanzhou University, an Affiliate of the Cochrane China Network, Lanzhou 730000, China
- 16. Chinese GRADE Center, Lanzhou 730000, China
- Key Laboratory of Evidence Based Medicine and Knowledge Translation of Gansu Province, Lanzhou University, Lanzhou 730000, China
- \* These authors contributed equally to this work.

**Correspondence to:** Chenyan Zhou. Department of Pediatric, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu 611731, China. Email: <u>dian\_z@163.com</u>; Donghong Peng. Department of Respiratory Medicine, Children's Hospital of Chongqing Medical University, Chongqing 400014, China. Email: <u>400713@hospital.cqmu.edu.cn</u>.

# Abstract

**Background:** Glucocorticoids are widely used in the treatment of various pulmonary inflammatory diseases, but they are also often accompanied by significant adverse reactions. Published guidelines point out that low dose and short duration systemic glucocorticoid therapy may be considered for patients with rapidly progressing COVID-19 while the evidence is still limited.

**Methods**: We comprehensively searched electronic databases and supplemented the screening by conducting a manual search. We included RCTs and cohort studies evaluating the effectiveness and safety of glucocorticoids in children and adults with COVID-19, SARS and MERS, and conducted meta-analyses of the main indicators that were identified in the studies.

**Results**: Our search retrieved 23 studies, including one RCT and 22 cohort studies, with a total of 13,815 patients. In adults with COVID-19, the use of systemic glucocorticoid did not reduce mortality (RR=2.00, 95% CI: 0.69 to 5.75, P=90.9%) or the duration of lung inflammation (WMD=-1 days, 95% CI: -2.91 to 0.91), while a significant reduction was found in the duration of fever (WMD=-3.23 days, 95% CI: -3.56 to -2.90). In patients with SARS, glucocorticoids also did not reduce the mortality (RR=1.52, 95% CI: 0.89 to 2.60, P=84.6%), duration of fever (WMD=0.82 days, 95% CI: -2.88 to 4.52, P=97.9%) or duration of lung inflammation absorption

(WMD=0.95 days, 95% CI: -7.57 to 9.48, *I*<sup>2</sup>=94.6%). The use of systemic glucocorticoid therapy prolonged the duration of hospital stay in all patients (COVID-19, SARS and MERS).

**Conclusions**: Glucocorticoid therapy was found to reduce the duration of fever, but not mortality, duration of hospitalization or lung inflammation absorption. Long-term use of high-dose glucocorticoids increased the risk of adverse reactions such as coinfections, so routine use of systemic glucocorticoids for patients with COVID-19 cannot be recommend.

Keywords: COVID-19; glucocorticoids; meta-analysis; rapid review

# Background

An infectious disease caused by a previously unknown type of coronavirus, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), emerged at the end of December 2019 and has posed a major challenge to the public health worldwide (1). The World Health Organization (WHO) officially named the disease as Corona Virus Disease 2019 (COVID-19) on February 11, 2020 (2). On March 11, 2020, the WHO declared COVID-19 as a global pandemic (3). Globally, as of 2:00am CEST, 12 April 2020, there have been 1,699,595 confirmed cases of COVID-19, including 106,138 deaths, reported to WHO (4).

At present, there are no specific drugs for the prevention and treatment of COVID-19, and symptomatic supportive treatment remains the most effective method of care. Full-genome sequencing and phylogenetic analyses have indicated SARS-CoV-2 is a distinct clade of beta-coronaviruses, related to the Middle East Respiratory Syndrome Coronavirus (MERS-CoV) and Severe Acute Respiratory Syndrome coronavirus (SARS-CoV). Therefore, the management of COVID-19 can benefit from experience from the SARS and MERS epidemics (5). Glucocorticoids were commonly used for the treatment of SARS and MERS especially in critically ill people (6-7), and are also widely used in the treatment of COVID-19.

There are conflicting opinions about the use of glucocorticoids to treat patients with COVID-19. It is suggested that current clinical evidence does not support the use of glucocorticoids, which may cause several side effects (8-9). However, clinicians who are on the front line of the epidemic have proposed that short-term glucocorticoid therapy with small or medium dose could be beneficial for patients with severe conditions (10). The current guidelines on COVID-19 are also inconsistent about the use of glucocorticoids. Some guidelines suggested trying short-term therapy with medium or small doses of glucocorticoids for patients with rapid or severe disease progression, but according to the WHO guidelines glucocorticoids should only be used under clinical trial conditions (11-13). Effective evidence related to glucocorticoids to treat COVID-19 is still lacking.

Therefore, the purpose of this study is to systematically retrieve and summarize the current evidence of the effectiveness and safety of glucocorticoid therapy for patients with COVID-19, aiming to provide the best decision-making basis for the prevention and control of the COVID-19 epidemic.

# Methods

#### Search strategy

Two experienced librarians searched the following databases from January 1st, 2003 to March 31th, 2020: The Cochrane library, MEDLINE (via PubMed), Embase, Web of Science, CBM (China Biology Medicine), CNKI (China National Knowledge

Infrastructure), and Wanfang Data. We used the following search: ("COVID-19" OR "SARS-CoV-2" OR "2019 novel coronavirus" OR "2019-nCoV" OR "Wuhan coronavirus" OR "novel coronavirus" OR "Wuhan seafood market pneumonia virus" OR "Wuhan virus" OR "MERS" OR "SARS" OR "Severe Acute Respiratory Syndrome" OR "Middle East Respiratory Syndrome Coronavirus" OR "Influenza") AND ("adrenal cortex hormones" OR " betamethasone valerate " OR " glucocorticoids" OR "methylprednisolone" OR "Cortisone" OR "Dexamethasone" OR "Cortodoxone" OR "Hydrocortisone"). We also searched clinical trial registry platforms (the World Health Organization Clinical Trials Registry Platform, US National Institutes of Health Trials Register and the International Standard Randomized Controlled Trial Number (ISRCTN) Register), Google Scholar (https://scholar.google.nl/) and preprint platforms BioRxiv (https://www.biorxiv.org/), MedRxiv (https://www.medrxiv.org/) and SSRN (https://www.ssrn.com/index.cfm/en/). In addition, we searched the reference lists of the identified systematic reviews to find further potential studies, and supplemented screening Google Scholar by conducting a manual search every day before submission. The search strategy was constructed with the assistance of a specialist in information retrieval (15). The details of the search strategy can be found in the Supplementary Material 1.

#### Inclusion and exclusion criteria

We included all studies on glucocorticoid therapy for patients diagnosed with COVID-19, SARS or MERS, without restricting the diagnostic criteria. We included

randomized controlled trials (RCTs) and cohort studies comparing glucocorticoid therapy versus placebo or comparing a combination of glucocorticoids and symptomatic treatment with symptomatic treatment alone. The primary outcome of interest was mortality, and secondary outcomes included duration of lung inflammation absorption, duration of hospital stay, duration of fever, and other adverse effects like coinfections (bacterial or fungal infections), kaliopenia, and osteonecrosis of femoral head (ONFH).

We excluded conference abstracts, articles written in languages other than English or Chinese and studies where we could not retrieve the full text or essential data were missing. All the reasons for exclusion of ineligible studies were recorded, and the process of study selection was documented using a PRISMA flow diagram (14).

### Study selection

After eliminating duplicates, two researchers (S Lu and L Huang) independently screened the literature in two steps using the EndNote software. In the first step, all titles and abstracts were screened using pre-defined criteria to exclude irrelevant articles. In the second step, full-texts of the potentially eligible and unclear studies were reviewed to decide about final inclusion. Disagreements were discussed or solved with a third researcher (Q Shi). All the reasons for exclusion of ineligible studies were recorded, and the process of study selection was documented using a PRISMA flow diagram (16).

#### **Data extraction**

Two researchers (S Lu and Q Zhou) independently extracted the data and information from all included studies by using a standardized data collection form. Extracted data included 1) basic information: first author, publication year, and the type of study design; 2) participants: disease, severity of disease, age distribution, and total number of patients; 3) details of the intervention and control groups: type, dosage and treatment course of glucocorticoid therapy; and 4) outcomes: for dichotomous data, we abstracted the number of events and total number of patients per group; and for continuous data, we abstracted the means, standard deviations (SD), and the total number of patients per group. For data that were missing or reported in unusable way, we reported the findings descriptively.

#### **Risk of bias assessment**

Two researchers (S Lu and S Zhao) independently assessed the potential bias in each included study, and discrepancies were resolved by discussion or consulting a third researcher (Q Shi). We assessed the risk of bias in RCTs using the Cochrane risk-of-bias tool (17), which consists of seven domains: random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data, selective outcome reporting, and other bias. Each domain was graded as "Low", "Unclear", or "High". For cohort studies, we used the Newcastle-Ottawa Scale (NOS) (18), which contains eight domains: representativeness of exposure cohorts, selection of non-exposure cohorts, determination of exposure, outcome events that did not occur before study initiation,

comparability of cohort based on design or analysis, assessment of outcome events, adequacy of follow-up time, and completeness of follow-up.

### **Quality of the evidence**

Two researchers (Zhou Q and Shi Q) assessed the quality of evidence independently using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) tool (19-20). We produced a "Summary of Findings" table using the GRADEpro software. The quality of evidence can be downgraded based on five factors (study limitations, consistency of effect, imprecision, indirectness and publication bias) and upgraded based on three factors (large magnitude of effect, dose-response relation and plausible confounders or biases) (21-26). The quality of evidence of each outcome is then classified as "high", "moderate", "low" or "very low".

#### Data synthesis

We conducted meta-analyses by using Stata 14 software (Stata Corp LLC). For dichotomous data, we calculated risk ratios (RR) with 95% confidence intervals (CI); for continuous data, we calculated weighted mean differences (WMD) with 95% CI. Missing data were dealt with according to the Cochrane Handbook for Systematic Reviews of Interventions (27). As clinical and methodological heterogeneity in study design, characteristics of participants, interventions and outcome measures was expected, we used random-effects models (28). Two-sided *P* values <0.05 were considered statistically significant. Statistical heterogeneity was assessed with the  $I^2$  statistic, >50% indicating substantial heterogeneity. If we detected heterogeneity, we performed subgroup analyses by the severity of the disease or the age of patients, and also considered sensitivity analyses where one study was excluded at a time. Egger test was used to assess publication bias (14). Each comparison is presented by the name of the first author and the year of publication.

As COVID-19 is a public health emergency of international concern and the situation is evolving rapidly, our study was not registered in order to speed up the process.

# Results

#### **Basic characteristics**

The rapid review identified 2509 publications, of which 23 studies (one RCT and 22 cohort studies) (29-51) met our inclusion criteria and were included. The literature screening process is shown in *Figure 1*. One study included adult patients with severe MERS, 17 studies included patients with SARS, and the remaining five studies were on patients with COVID-19 (*Table 1*). Due to the insufficient representativeness and follow-up time, only three articles scored higher than six out of nine points. The methodological quality of included cohort studies was poor. The risk of bias of included RCT was unclear because of unclear risks of selection bias, detection bias and reporting bias (*Table 2, Table 3*).

#### **Meta-analyses**

Mortality was assessed in thirteen cohort studies (four on COVID-19, eight on SARS,

one on severe MERS) (29-41) with a total of 11,211 patients. The use of systemic glucocorticoid did not reduce the risk of death in COVID-19 (RR=2.0, 95% CI: 0.7 to 5.8,  $I^2$ =90.9%) or SARS patients (RR=1.5, 95% CI: 0.9 to 2.6,  $I^2$ =84.6%). Subgroup analyses showed that glucocorticoids also did not reduce the risk of death in severe cases of SARS (RR=1.3, 95% CI: 0.5 to 3.3,  $I^2$ =67.4%) or in adults (RR=1.1, 95% CI: 0.7 to 1.8,  $I^2$ =68.7%). In mild cases of SARS glucocorticoids even increased the risk of death (RR=3.6, 95% CI: 1.9 to 6.9). In adult patients with MERS, the use of glucocorticoid increased mortality (RR=1.3, 95% CI: 1.1 to 1.5) (*Figure 2, Figure 3, Figure 4*).

Five cohort studies with a total of 4709 patients assessed the duration of fever in COVID-19 (one study) and SARS (four studies) patients (30,32,35,40,42). The duration of fever was significantly lower in COVID-19 patients who received glucocorticoid treatment than in patients who received no glucocorticoid treatment (WMD=-3.2 d, 95% CI: -3.6 to -2.9), while for SARS patients there was no difference (WMD=0.8 d, 95% CI: -2.9 to 4.5, *P*=97.9%). Subgroup analysis showed that glucocorticoid use did not shorten the duration of fever neither in patients with severe SARS (WMD=-1.1 d, 95% CI: -4.9 to 2.7, *P*=58.3%) nor in patients with mild SARS (WMD=0.5 d, 95% CI: -4.2 to 5.1, *P*=95.1%) (*Figure 5, Figure 6*).

Three cohort studies assessed the duration of lung inflammation absorption in patients with COVID-19 (one study) and SARS (two studies) (30,42,43). No difference between patients who received or did not receive glucocorticoid treatment was found

in neither COVID-19 (WMD=-1.0 d, 95% CI: -2.9 to 0.9) nor SARS (WMD=1.0 d, 95% CI: -7.6 to 9.5,  $I^2$ =94.6%) patients. Subgroup analyses showed that using glucocorticoids did not shorten the absorption time of lung inflammation in patients with severe SARS regardless of severity (WMD=0.4 d, 95%CI: -4.2 to 5.1,  $I^2$ =0%), or with mild SARS (WMD=1.3 d, 95%CI:-8.7 to 11.3,  $I^2$ =95.5%) (*Figure 7, Figure 8*).

Five cohort studies (one on COVID-19, three on SARS, one on severe MERS) with a total of 5872 patients assessed the duration of hospital stay (29,31,35,37,41). Patients treated with glucocorticoids stayed longer in the hospital than patients who did not receive glucocorticoids (COVID-19: WMD=2.4 d, 95%CI: 1.4 to 3.4,  $I^2$ =0.0%; SARS: WMD=6.8 d, 95%CI: 1.5 to 12.2,  $I^2$ =94.2%; MERS: WMD=6.3 d, 95%CI: 2.4 to 10.2) (*Figure 9*).

Five cohort studies with a total of 5302 patients assessed the adverse outcomes in patients with SARS (29, 30, 35, 44, 45). Glucocorticoid use increased the risk of coinfections (bacterial or fungal) (RR=3.5, 95% CI: 2.3 to 5.3, *I*<sup>2</sup>=0%), MODS (RR=3.9, 95% CI: 2.1 to 6.9), and Acute Respiratory Distress Syndrome (ARDS) (RR=6.1, 95% CI: 3.2 to 11.5), while no significant association on DIC, hypokalemia, hypocalcemia and ONFH was found (*Figure 10*).

### **Quality of evidence**

The quality of evidence on the results on mortality in COVID-19 and SARS studies, of very low quality, and in MERS studies of low quality (*Tables 4-6*).

#### Sensitivity Analysis

Heterogeneity among studies on SARS assessing mortality was significant ( $l^2$ =84.6%). Heterogeneity in studies of mortality in SARS patients was reduced to 67.4% in the subgroup analysis of severe cases, and to 68.7% in the subgroup analysis of adults. Therefore, disease severity and age are probably the main sources of heterogeneity in the meta-analysis of mortality. We conducted a sensitivity analysis on the on the SARS mortality by omitting one study at a time. Two studies had a significant impact on the results of the meta-analysis (34, 35) (*Figure 11*). The dosing of glucocorticoids was different in the study by Yam *et al* than in other studies, so the high heterogeneity in the meta-analysis on mortality may be at least partly caused by the different dosing (34).

### **Publication Bias**

We assessed publication bias was for the eight studies on SARS mortality. The Egger regression test showed that publication bias was unlikely (P=0.619) (*Figure 12*).

# Discussion

Our study identified direct evidence on the clinical efficacy of glucocorticoid therapy for five difference outcomes in adults with COVID-19. Evidence of low to very low-quality showed that glucocorticoid therapy significantly reduced the duration of

fever, but not the risk of death and lung inflammation absorption in patients with COVID-19 or SARS. In addition, glucocorticoid therapy may even prolong the duration of hospitalization. Long-term use of high-dose glucocorticoids increased the risk of adverse reactions such as infections and osteonecrosis. We found moderate-quality evidence that in patients with mild SARS glucocorticoids may be associated with a more than three-fold increase in the risk of death.

Systemic glucocorticoids are highly effective anti-inflammatory drugs, but their use against SARS-CoV-2 infection remains controversial. A case series of children with COVID-19 in Hubei reported that systematic glucocorticoids (dose 2 mg/kg) were given to both two included critical cases in combination with invasive mechanical ventilation and intravenous immunoglobulin. In both children, the symptoms on admission were alleviated, although in one of them only partly (52). A recent cohort study from JAMA Internal Medicine reported that among COVID-19 patients with ARDS, treatment with methylprednisolone decreased the risk of death (39). Our results are compared with published systematic reviews of glucocorticoid therapy for severe pneumonia. A recent rapid review of COVID-19 treatment showed controversial evidence on the use of corticosteroids, and could not give any suggestion on the use of corticosteroids due to the lack of quantitative synthesis (53). A systematic review covering in vitro studies on SARS, SARS in humans and other diseases such as ARDS, found that 25 of the 29 included studies were inconclusive, and the remaining four found glucocorticoids harmful (54). A recent systematic review of influenza

pneumonia showed that glucocorticoid therapy increased the risk of death (RR=1.75, 95% CI: 1.30-2.36), length of ICU stay (RR=2.14 days, 95% CI: 1.17-3.10), and risk of secondary infections (RR=1.98, 95% CI: 1.04-3.78) (55). A meta-analysis of SARS in 2017 showed that the incidence of osteonecrosis increased with the dosing of systemic glucocorticoids, and the summary RR of osteonecrosis was 1.57 (95% CI 1.30–1.89) (56). As retrospective studies have shown that the glucocorticoids were given for 19% to 26% of patients with COVID-19 (and to 45% of patients with severe disease), there is a high risk that this therapy is currently misused (57-59). In summary, the current research evidence does not support the routine use of systemic glucocorticoids for patients with COVID-19. Because COVID-19 tends to be less severe in children than in adults (60), the use of systemic glucocorticoids should in particular not be recommended in children.

#### **Strengths and Limitations**

This is to our knowledge the first comprehensive and systematic review of the effectiveness and safety of glucocorticoid therapy for patients with COVID-19 using data from the COVID-19 studies, and can be considered at the moment as the best evidence for decision-making on this topic. We conducted meta-analyses to quantitatively synthesize the findings of the included studies and objectively evaluate the current research evidence. Our study had also several limitations. We found only limited direct evidence of systemic glucocorticoids therapy for COVID-19, and had to use indirect evidence from the SARS and MERS epidemics. We also could not conduct

subgroup analyses according to the dose and type of glucocorticoids because of the small number of studies.

# Conclusions

In conclusion, glucocorticoid therapy may increase the risk of death in patients with coronavirus infections who have mild symptoms. We found no association between glucocorticoids and mortality in patients with severe symptoms. In the context of clinical trials, low dose systemic glucocorticoid therapy for a short duration may be acceptable.

# **Author contributions**

(I) Conception and design: Lu S, Zhou Q and Huang L; (II) Administrative support: Y Chen; (III) Provision of study materials or patients: Lu S, Huang L, Zhou Q; (IV) Collection and assembly of data: Lu S, Zhou Q and Shi Q; (V) Data analysis and interpretation: Zhou Q, Lu S and Zhao S; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.

# Funding

This work was supported by grants from National Clinical Research Center for Child Health and Disorders (Children's Hospital of Chongqing Medical University, Chongqing, China) (grant number NCRCCHD-2020-EP-01); Special Fund for Key

Research and Development Projects in Gansu Province in 2020; The fourth batch of "Special Project of Science and Technology for Emergency Response to COVID-19" of Chongqing Science and Technology Bureau. Special funding for prevention and control of emergency of COVID-19 from Key Laboratory of Evidence Based Medicine and Knowledge Translation of Gansu Province (grant number No. GSEBMKT-2020YJ01).

# Acknowledgments

We thank Janne Estill, Institute of Global Health of University of Geneva for providing guidance and comments for our review. We thank all the authors for their wonderful collaboration.

# Footnote

Conflicts of Interest: The authors have no conflicts of interest to declare.

**Ethical Statement:** The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

# References

- 1. Phelan AL, Katz R, Gostin LO. The Novel Coronavirus Originating in Wuhan, China: Challenges for Global Health Governance [published online ahead of print, 2020 Jan 30]. JAMA 2020;10.1001/jama.2020.1097.
- WHO Director-General's remarks at the media briefing on 2019-nCoV on 11 February 2020[Internet]. World Health Organization 2020 [cited 2020 Apr 13]. Available online: https://www.who.int/dg/speeches/detail/who-director-general-s-remarks-at-the-media-briefing-on-2019-ncovon-11-february-2020.
- 3. WHO characterizes COVID-19 as a pandemic. March 12, 2020[Internet]. World Health Organization 2020

20		

[cited	2020	Apr	13].	Available	online:
https://www.	who.int/emergencies/	diseases/novel-co	ronavirus-2019/ever	nts-as-they-happen.	

 Coronavirus (COVID-19) [Internet]. World Health Organization 2020 [cited 2020 Apr 13]. Available online: https://who.sprinklr.com/.

- Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, et al. Genomic characterization and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet 2020 Jan 30. pii: S0140-6736(20)30251-8.
- 6. So LK, Lau AC, Yam LY, et al. Development of a standard treatment protocol for severe acute respiratory syndrome. Lancet 2003;361:1615–7.
- Arabi YM, Al-Omari A, Mandourah Y, et al.; Saudi Critical Care Trial Group. Critically ill patients with the Middle East respiratory syndrome: a multicenter retrospective cohort study. Crit Care Med 2017;45:1683–95.
- 8. Clark D Russell, Jonathan E Millar, J Kenneth Baillie. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. Lancet, Published Online February 6, 2020.
- 9. Shang L, Zhao J, Hu Y, Du R, Cao B. On the use of corticosteroids for 2019-nCoV pneumonia. Lancet 2020 Feb 29;395:683-4.Epub 2020 Feb 12.
- 10. Chen Z, Fu J, Shu Q et al. Diagnosis and treatment recommendations for pediatric respiratory infection caused by the 2019 novel coronavirus. World J Pediatr 2020. https://doi.org/10.1007/s12519-020-00345-5
- Jin YH, Cai L, Cheng ZS, et al. A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version). Mil Med Res 2020;7(1):4. Published 2020 Feb 6.
- 12. Clinical management of severe acute respiratory infection (SARI) when COVID-19 disease is suspected[Internet]. World Health Organization March 2020 [cited 2020 Apr 13]. Available online: https://apps.who.int/iris/bitstream/handle/10665/331446/WHO-2019-nCoV-clinical-2020.4-eng.pdf
- Novel Coronavirus(2019-nCoV) Situation Report 33[Internet]. World Health Organization 2020 [cited 2020 Apr 13]. Available from:https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports
- 14. Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009;6:e1000097.
- 15. Li L, Tian J, Tian H, et al. Network meta-analyses could be improved by searching more sources and by involving a librarian. J Clin Epidemiol 2014; 67: 1001-7.
- 16. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med 2009;6:e1000100.
- 17. Higgins, J. P. T, Altman, D. G, Gotzsche, P. C, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ 2011;343:d5928. Published 2011 Oct 18.
- Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 2010;25:603–5.
- 19. Guyatt G, Oxman AD, Akl EA, et al. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol 2011;64:383–94.
- 20. Norris, SL; Meerpohl, JJ; Akl, EA; Schunemann, HJ; Gartlehner, G; Chen, YL; Whittington, C. The skills and experience of GRADE methodologists can be assessed with a simple tool. JOURNAL OF CLINICAL EPIDEMIOLOGY 2016; 79: 150-8.
- 21. Guyatt GH, Oxman AD, Vist G, et al. GRADE guidelines: 4. Rating the quality of evidence--study limitations (risk of bias). J Clin Epidemiol 2011;64:407–15.
- 22. Guyatt GH, Oxman AD, Montori V, et al. GRADE guidelines: 5. Rating the quality of evidence--publication bias. J Clin Epidemiol 2011;64:1277–82.
- Guyatt GH, Oxman AD, Kunz R, et al. GRADE guidelines 6. Rating the quality of evidence--imprecision. J Clin Epidemiol 2011;64:1283–93.
- Guyatt GH, Oxman AD, Kunz R, et al. GRADE guidelines: 7. Rating the quality of evidence--inconsistency. J Clin Epidemiol 2011;64:1294–02.
- 25. Guyatt GH, Oxman AD, Kunz R, et al. GRADE guidelines: 8. Rating the quality of evidence--indirectness. J Clin Epidemiol 2011;64:1303–10.
- Guyatt GH, Oxman AD, Sultan S, et al. GRADE guidelines: 9. Rating up the quality of evidence. J Clin Epidemiol 2011;64:1311–6.
- Cumpston M, Li T, Page MJ, Chandler J, Welch VA, Higgins JP, Thomas J. Updated guidance for trusted systematic reviews: a new edition of the Cochrane Handbook for Systematic Reviews of Interventions. Cochrane Database Syst Rev 2019 Oct 3;10:ED000142.
- 28. DerSimonian R, Kacker R. Random-effects model for meta-analysis of clinical trials: an update. Contemp Clin Trials 2007;28:105–14.
- 29. Meng Q, Dong P, Guo Y, et al. A preliminary study on the treatment of severe acute respiratory syndrome with glucocorticoid. Chinese Journal of Preventive Medicine 2003;37:233-5.
- 30. Peng J, Hou J, Guo Y, et al. Discussion on the treatment of SARS with glucocorticoid. Medical Journal of

Chinese People's Liberation Army 2004;29:752-753.

- Wang G, Li N, Wu Y, et al. Multifactor COX regression analysis of adrenal glucocorticoid use in patients with severe acute respiratory syndrome. Chin J Med 2004;84:1073-8.
- 32. Wang P, Li M, Shi Y, et al. (Evaluating the effects of different treatments on severe acute respiratory syndrome). Shanxi Medical Journal 2005;34:270-2.
- 33. Chen R , Tang X , Tan S, et al. Treatment of Severe Acute Respiratory Syndrome With Glucosteroids : The Guangzhou Experience. Chest 2006;129:1441-52.
- Yam L, Lau A, Lai F, et al. Corticosteroid treatment of severe acute respiratory syndrome in Hong Kong. J Infect 2007;54:28–39.
- 35. Ma F. Study on the application value of glucocorticoid in the treatment of SARS. Huazhong University of Science and Technology 2008.
- Lau E, Cowling B, Muller M, et al. Effectiveness of ribavirin and corticosteroids for severe acute respiratory syndrome .Am. J. Med 2009;122: 1150.e11-21.
- 37. Arabi Y, Mandourah Y, Al-Hameed F, et al. Corticosteroid Therapy for Critically Ill Patients with Middle East Respiratory Syndrome .Am. J. Respir. Crit. Care Med 2018;197: 757-67.
- Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study [published correction appears in Lancet 2020 Mar 28;395(10229):1038]. Lancet 2020;395(10229):1054–1062.
- Wu C, Chen X, Cai Y, et al. Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China. JAMA Intern Med 2020 Mar 13:e200994.
- 40. Wang Y, Jiang W, He Q, et al. Early, low-dose and short-term application of corticosteroid treatment in patients with severe COVID-19 pneumonia: single-center experience from Wuhan, China. medRxiv 2020[cited 2020 Apr 13] Available online: https://www.medrxiv.org/content/10.1101/2020.03.06.20032342v1
- 41. Shang J, Du R, Lu Q, et al. The Treatment and Outcomes of Patients with COVID-19 in Hubei, China: A Multi-Centered, Retrospective, Observational Study (2/26/2020). SSRN 2020 [cited 2020 Apr 13]. Available online:https://papers.ssrn.com/sol3/papers.cfm?abstract\_id=3546060
- 42. Ding K, Xu Z, Huang H, et al. [Retrospective Analysis of the Glucocorticoid Treatment in 409 Patients with Severe Acute Respiratory Syndrome]. Applies Journal of General Practice 2005,3:193-4.
- Ni Q, Ding C, Li Y, et al.[A retrospective study of virus clearance in patients with COVID-19 treated with low

   and medium-dose glucocorticoids]. Chinese journal of clinical infection 2020,13 (2020-02-28). http://rs.yiigle.com/yufabiao/1182773.htm.
- 44. He R, Liu Z, Duan X. [Adverse effects associated with corticosteroids therapy in 57 SARS cases]. Adverse Drug Reactions Journal 2003;5:374-7.
- 45. Shen J, Liang B, Zeng Q, et al. MR imaging of proximal femoral bone marrow in patients with severe acute respiratory syndrome. Chin J Tuberc Respir Dis 2006;29:189-93.
- Hu W, Wang L. [Effect of glucocorticoid therapy upon glucose metabolism in SARS patients). Beijing medical 2004;25:400-2.
- 47. Jin M, Tong X, Wei Y, et al.[Observing the influence to the intraocular pressure of patients with severe acute respiratory syndrome]. Journal of Traditional Chinese Ophthalmology 2004;14:7-9.
- 48. Lee N, Allen Chan K, Hui D, et al. Effects of early corticosteroid treatment on plasma SARS-associated Coronavirus RNA concentrations in adult patients .J. Clin. Virol 2004;31: 304-9.
- 49. Li N, Wang G, Wu Y, et al. [Clinical diagnosis of SARS: analysis of adverse reactions to glucocorticoid therapy in 1291 cases]. Journal of Peking University(Health Sciences) 2004;36:519-524.
- 50. Zhou Y, Zhang Y, Li Y, et al. [Effect of short-term application of methylprednisolone on blood glucose level in patients with infectious SARS]. Chinese Journal of Diabetes Mellitus 2004;:31-34.
- 51. Auyeung T,Lee J ,Lai W, et al. The use of corticosteroid as treatment in SARS was associated with adverse outcomes: a retrospective cohort study. J. Infect 2005;51: 98-102.
- 52. Zheng F,Liao C,Fan Q, et al. Clinical Characteristics of Children with Coronavirus Disease 2019 in Hubei, China.Curr Med Sci 2020;Mar 24.
- 53. Song Y,Zhang M,Yin L,et al. COVID-19 Treatment: Close to a Cure? A Rapid Review of Pharmacotherapies for the Novel Coronavirus. Preprints 2020, 2020030378.doi: 10.20944/preprints202003.0378.v1.
- 54. Stockman LJ, Bellamy R, Garner P. SARS: systematic review of treatment effects.PLoS Med 2006;Sep;3:e343.
- 55. Ni YN, Chen G, Sun J, Liang BM, Liang ZA. The effect of corticosteroids on mortality of patients with influenza pneumonia: a systematic review and meta-analysis. Critical Care 2019 Dec;23:99.
- Zhao R, Wang H, Wang X, Feng F. Steroid therapy and the risk of osteonecrosis in SARS patients: a dose-response meta-analysis. Osteoporos Int 2017;28:1027–34.
- Guan WJ, Ni ZY, Hu Y, et al. Clinical Characteristics of Coronavirus Disease 2019 in China [published online ahead of print, 2020 Feb 28]. N Engl J Med. 2020;NEJMoa2002032.
- 58. Xu XW, Wu XX, Jiang XG, et al. Clinical findings in a group of patients infected with the 2019 novel

22

coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series. BMJ 2020 Feb 19;368. 59. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z. Clinical features of

- patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet 2020 Feb 15;395:497-506.
- 60. Dong Y, Mo X, Hu Y, et al. Epidemiological characteristics of 2143 pediatric patients with 2019 coronavirus disease in China. Pediatrics 2020; doi: 10.1542/peds.2020-0702

						Table 1	Characteristi	ics of include	d studies			
Study ID	R/P	Study design	Disease	Severity of disease	Population	Number of patients	I (Age, years)	C (Age, years)	I (male /female)	C (male /female)	Type, dose and duration of glucocorticoid therapy	Outcomes
eng 2003 9)	R	Cohort	SARS	N/A	Adult	70	33±15		18/	70	Methylprednisolone, low dose for 40-80mg/d; mild dose for 120-240mg/d; high dose for 320-640mg/d. The dosage reduced from 10-15d, 1/3-1/2 should be subtracted for the first time, According to the severity of the disease, 1/2 of the applied dose should be decreased for every 3 to 5 days. When most of the lesion is absorbed, the patient can be discharged with the drug (20mg/d prednisone).	ĵ ⊕ 2
eng 2004 30)	R	Cohort	SARS	Mild/Severe	Both	99	38.9	37.6	22/46	27/53	Dexamethasone 10mg/d ; Methylprednisolone 80mg/d , 3-8d.	1232
ang 2004 1)	R	Cohort	SARS	N/A	Both	1291	37±15	36±17	500/1084	121/207	Methylprednisolone	1
ang 2005 2)	R	Cohort	SARS	N/A	Both	241	35±12	32±16	94/192	29/49	Methylprednisokne, Dexamethasone and Hydrocortisone.	124
hen 2006 3)	R	Cohort	SARS	Mild/Severe	Both	401	34.7±13.3		129/401	X	Noncritical 105.3±86.1 mg/d; Critical, 133.5±102.3 mg/d;	2
7am 2007 34)	R	Cohort	SARS	N/A	Adult	1287	60.7±30.4		1021/1188	56/99	Hydrocortisone ;intravenous Methylprednisolone; oral prednisolone; intravenous pulsed	2

											Corticosteroid≥500mg/d. <i>Rescue Pulse</i> is defined as intravenous methylprednisolone administered at 500 mg or more per dose for at least 1 day started after at least 1 day of corticosteroid treatment. Prednisone, Dexamethasone, Hydrocortisone,	1000
Ma 2008 (35)	R	Cohort	SARS	Mild/Severe	Both	4887	37.4±15.3	36.1±17.5	1703/3612	670/127 5	prednisolone et al.	13.46
Lau 2009 (36)	R	Cohort	SARS	N/A	Adult	1889	>16		327/829	504/106 0	Corticosteroids	2
Arabi 2018 (37)	R	Cohort	MERS	Severe	Adult	309	57.8±17.2	55.3±17.3	107/151	106/158	Hydrocortisone, 3d	145
Zhou 2020 (38)	R	Cohort	COVID-1 9	All	Adult	191	56.3±15.7		119/72		Corticosteroids	2
Wu 2020 (39)	R	Cohort	COVID-1 9	Severe	Adult	201	51.3±12.7		128/73		Methylprednisolone	2
Yin 2020 (40)	R	Cohort	COVID-1 9	Severe	Adult	46	55.0±11.8	54.7±12.0	16/10	10/10	Methylprednisolone	10
Shang 2020 (41)	R	Cohort	COVID-1 9	Mild/Severe	Adult	416	48.7±18.6		197/219		methylprednisolone	14
Ding 2005 (42)	R	Cohort	SARS	Mild/Severe	Mixed	409	36.8±14.4		170/409	Х	Methylprednisolone	23
Ni 2020 (43)	R	Cohort	COVID-1 9	Mild/Severe	Adult	72	53.0±13.0	44.7±19.1	29/22	12/9	Methylprednisolone	3

He 2003 (44) Shen 2006 (45)	R R	Cohort Cohort	SARS SARS	N/A N/A	Both Adult	98 148	8~72 † N/A		46/98 32/148	x x	Methylprednisolone 80-480mg/d, 5-7d; change to prednisolone when reduced to 40mg/d; reduce 5mg every 3-5 days until discontinued Prednisone 59mg/d(mean); 2-87d, 24d(mean)	@ (†) (2) 12
Hu 2003 (46)	R	Cohort	SARS	N/A	Both	214	40.8±17.3	38.9±18.8	80/156	32/58	Methylprednisolone (mean dose 187mg/d , maximum dose 1000mg/d); gradually reduce the dose and switch to oral prednisone (5~50mg/d , mean dose 23mg/d); The average duration of glucocorticoids use during hospitalization was	6
Jin 2004 (47)	R	Cohort	SARS	Mild/Severe	Adult	58	18~78 †		27/58	Х	24.38d. Methylprednisolone 80-320mg/d. Dosage can be appropriately increased if necessary, large dosage time should not be too long. The specific dosage is adjusted according to the condition, and the dosage is gradually reduced and discontinued after the remission of the condition or the absorption of the chest film shadow.	8
Lee 2004 (48)	Р	RCT	SARS	N/A	Adult	16	22~57 †		2/9	2/7	Hydrocortisone 100mg/q8h for 12 days. Until "pulse" methylprednisolone was given as rescue therapy. "Pulse" of intravenous high-dose methylprednisolone (500 mg/day for three consecutive days) was given for cases having persistent/recurrent fever plus radiographic progression of lung opacities ± hypoxemia as	0

Li 2004 (49) Zhou 2004 (50)	R R	Cohort Cohort	SARS SARS	N/A N/A	Both Adult	1291 103	37±15 36±12	36±17 35±14	500/1084 23/39	121/207 41/64	rescue therapy. Methylprednisolone (early average daily dose (median): 160mg/d); After 10 days it went down to 80mg/d in 13 days and 40mg/d in 21 days. Methylprednisolone 80-320mg/d, duration ( 12±4 ) d	0
Auyeung 2005 (51)	R	Cohort	SARS	Mild	Adult	78	18~89 †	43-95 †	27/66	6/12	Hydrocortisone 10mg/kg/d ; or methylprednisolone 1-3mg/kg/d; or pulse intravenous methylprednisolone 500-1000mg/d , 2-3d.	9

Outcomes : Duration of fever; Lung inflammation absorption time; Length of stay; Virus clearance; Fasting blood glucose levels; Maximum blood glucose levels;

Delevated intraocular pressure; DLDH peak; Hypokalemia; Hypocalcemia; Infection; MODS (Multiple Organ Dysfunction Syndrome); DIC (Disseminated Intravascular Coagulation);
 ARDS (Acute Respiratory Distress Syndrome); ONFH (Osteonecrosis of the Femoral Head)
 Intervention; C: Control; R/P: Retrospective/Prospective

†: minimum and maximum

			Table 2 Assessment of risk	c of bias in RCT			
Study	Selection bias		Performance bias	Detection bias	Attrition bias	<b>Reporting bias</b>	Other bias
	Random sequence	Allocation	Blinding of participants and	Blinding of outcome	Incomplete	Selective	
	generation	concealment	personnel	assessment	outcome data	reporting	

Lee 2004(48)	Unclear	Unclear	Low	Unclear	Low	Unclear	Unclear

			Tabl	e 3 Assessmen	t of risk bias in	cohort studies				
			Selec	tion		Comparability		Outcome		
Study	Туре	Representativen ess of the exposed cohort	Selection of the non-exposed cohort	Ascertainment of exposure	Demonstration that outcome of interest was not present at start of study	Comparability of cohorts on the basis of the design or analysis	Assessment of outcome	Was follow-up long enough for outcomes to occur	Adequacy of follow up of cohorts	NOS score
Meng 2003(29)	Cohort	1	1	0	1	1	1	0	1	6
Peng 2004(30)	Cohort	1	1	0	1	1	1	0	1	6
Wang 2004(31)	Cohort	1	1	1	0	0	1	0	1	5
Wang 2005(32)	Cohort	1	1	0	0	1	1	1	1	6
Chen 2006(33)	Cohort	0	0	1	0	0	1	1	1	4
Yam 2007(34)	Cohort	0	0	1	0	0	1	1	1	4
Ma 2008(35)	Cohort	1	1	1	1	1	1	0	1	7
Lau 2009(36)	Cohort	1	1	1	1	0	1	0	1	6
Arabi 2018(37)	Cohort	1	1	1	0	2	1	1	1	8
Zhou 2004(38)	Cohort	0	0	1	0	1	1	0	1	4
Wu 2020(39)	Cohort	1	1	1	1	0	1	0	0	5
Yin 2020(40)	Cohort	1	1	1	1	0	1	0	0	5

Shang 2020(41)	Cohort	1	1	1	1	0	1	0	0	5
Ding 2005(42)	Cohort	0	0	1	0	0	0	0	0	1
Ni 2020(43)	Cohort	1	1	1	1	0	1	0	0	5
He 2003(44)	Cohort	0	0	1	0	0	1	1	1	4
Shen 2006(45)	Cohort	0	1	0	1	1	1	0	0	4
Hu 2003(46)	Cohort	1	1	0	0	1	0	0	1	4
Jin 2004(47)	Cohort	0	0	1	0	0	1	1	1	4
Li 2004(49)	Cohort	1	1	1	0	2	1	0	1	7
Zhou 2020(50)	Cohort	1	1	1	1	1	1	0	0	6
Auyeung 2005(51)	Cohort	0	0	1	0	1	1	1	1	5

1	n
_	9

# Table 4 GRADE evidence profile of COVID-19 studies

№ of			Cei	tainty assessn	nent			№ of patients		Effect Value	Certainty
studies	Risk	of	Inconsistency	Indirectnes	Imprecisio	Other	Sample	Interventio	Contro	(95% CI)	
	bias			S	n	considerations	-	n	1		
Mortality											
CS (4)	not seriou	15	serious1	not serious	not serious	none	737	329	408	RR 2.00	$\oplus$ 2 2 2
										(0.69 to 5.75)	VERY LOW
Duration	of fever (d)	)									
CS (1)	serious2	!	not serious	not serious	not serious	none	46	26	20	WMD -3.23	⊕ 2 2 2 2
										(-3.56 to	VERY LOW
										-2.90)	
Lung infla	ammation a	ibso	rption time (d)								
CS (1)	serious2	!	not serious	not serious	not serious	none	72	51	21	WMD -1.00	⊕ 2 2 2
										(-2.91 to	VERY LOW
										0.91)	
Length of	hospital st	ay (c	1)								
CS (1)	serious2	!	not serious	not serious	not serious	none	365	153	212	WMD 2.43	⊕ 2 2 2
										(1.42 to 3.43)	VERY LOW

CS: Cohort study.

Explanations

1. downgrade one level: Heterogeneity of data synthesis results,  $I^2 > 50\%$ .

2. downgrade one level: The risk of bias is high due to the limitations of study design.

# Table 5 GRADE evidence profile of SARS studies

№ of		Ce	rtainty assessn	nent	№ of patients			Effect Value	Certainty	
studies	Risk o	of Inconsistency	Indirectnes	Imprecisio	Other	Sample	Interventio	Contro	(95% CI)	
	bias		S	n	considerations		n	1		
Mortality	y (All patient	s)								
CS (8)	not serious	s serious1	not serious	not serious	none	10165	7278	2887	RR 1.52 (0.89 to 2.60)	⊕222 VERY LOW
Mortality	y (Mild)									
CS (3)	not serious	s not serious	not serious	not serious	large magnitude of effect4	3871	2649	1222	RR 3.61 (1.88 to 6.92)	⊕⊕⊕ℤ MODERATE
Mortality	y (Severe)									
CS (3)	not serious	s serious1	not serious	not serious	none	1516	1277	239	RR 1.33 (0.54 to 3.30)	⊕222 VERY LOW
Mortality	y (Adult)									
CS (3)	not serious	s serious1	not serious	not serious	none	3246	2076	1170	RR 1.08 (0.66 to 1.76)	⊕222 VERY LOW
Duration	of fever (All	l patients) (d)								
CS (4)	not serious	s serious1	not serious	not serious	none	4663	3658	1005	WMD 0.82 (-2.88 to 4.52)	⊕222 VERY LOW
Duration	of fever ( M	ild ) (d)								
CS (2)	serious2	not serious	not serious	not serious	none	373	267	106	WMD 0.45 (-4.15 to 5.06)	⊕222 VERY LOW
Duration	of fever ( Se	evere) (d)							,	
CS (2)	serious2	not serious	not serious	not serious	none	131	108	23	WMD -1.12 (-4.94 to 2.70)	⊕222 VERY LOW
Lung inf	lammation at	osorption time (All J	patients) (d)							

CS (2)	not serious	serious1	not serious	not serious	none	504	375	129	WMD 0.95 (-7.57 to	⊕222 VERY LOW
Lunginfl	ammation abso	rption time (Mil	d) (d)						9.48)	
CS (2)	serious2	not serious	not serious	not serious	none	373	267	106	WMD 1.31 (-8.68 to 11.30)	⊕222 VERY LOW
Lung infl	ammation abso	rption time ( Sev	vere ) (d)						11.50)	
CS (2)	serious2	not serious	not serious	not serious	none	131	108	23	WMD 0.44 (-4.17 to 5.05)	⊕222 VERY LOW
CS (3)	not serious	All patients) (d) serious1	not serious	not serious	none	5198	3863	1335	WMD 6.83 (1.48 to 12.17)	⊕222 VERY LOW
Virus clea RCT(1 )	arance not serious	not serious	not serious	serious <sup>3</sup>	none	16	9	7	RR 0.91 (0.66 to 1.24)	⊕⊕⊕ℤ MODERATE
·	intraocular pres	sure (mmHg)							(0.00 to 1.2.)	
CS (1)	serious2	not serious	not serious	not serious	none	58	38	20	WMD 4.24 (2.39 to 6.09)	⊕222 VERY LOW
Peak LD CS (1)	serious2	not serious	not serious	not serious	none	78	66	12	WMD -309.50 (-1267.93 to 648.93)	⊕222 VERY LOW
Fasting bl CS (2)	lood glucose le <sup>,</sup> serious2	vels (two weeks) not serious	(mmol/l) not serious	not serious	none	317	195	122	WMD 1.66 (1.08 to 2.25)	⊕222 VERY LOW
	n blood sugar le									
CS (1)	serious2	not serious	not serious	not serious	none	1291	1084	207	WMD 2.29 (1.71 to 2.87)	⊕222 VERY LOW
Hypokale CS (1)	serious2	not serious	not serious	not serious	none	98	57	41	RR 2.16 (0.94 to 4.96)	⊕222 VERY LOW
Hypocalc CS (1)	emia serious2	not serious	not serious	not serious	none	98	57	41	RR 1.07 (0.81 to 1.41)	⊕222 VERY LOW
Infection CS (4)	serious2	not serious	not serious	not serious	none	5514	3774	1380	RR 3.52 (2.33 to 5.32)	⊕222 VERY LOW
MODS CS (1)	serious2	not serious	not serious	not serious	none	4887	3612	1275	RR 3.85	⊕222
DIC (Dis	seminated Intra	vascular Coagul	ation)						(2.14 to 6.94)	VERY LOW
CS (1)	serious2	not serious	not serious	not serious	none	4887	3612	1275	RR 9.54 (0.57 to 160.29)	⊕222 VERY LOW
ARDS CS (1)	serious2	not serious	not serious	not serious	none	4887	3612	1275	RR 6.07 (3.22 to 11.45)	⊕222 VERY LOW
ONFH (C CS (1)	Osteonecrosis of serious2	the Femeral He not serious	ad) not serious	not serious	none	148	106	42	RR 3.62 (0.20 to 65.75)	⊕222 VERY LOW

Explanations

1. downgrade one level: Heterogeneity of data synthesis results,  $I^2 > 50\%$ .

31

- 2. downgrade one level: The risk of bias is high due to the limitations of study design.
- 3. downgrade one level: Sample size is less than optimal information sample (OIS).
- 4. upgrade one level: Large magnitude of effect, RR>2.

# Table 6 GRADE evidence profile of MERS studies

№ of	Certainty assessment						№ of patients			Effect Value	Certainty
studies	Risk o	of	Inconsistency	Indirectnes	Imprecisio	Other	Sample	Interventio	Contro	(95% CI)	
	bias			S	n	considerations		n	1		
Mortality	/										
CS (1)	not seri	ous	not serious	not serious	not serious	none	309	151	158	RR 1.29	$\oplus \oplus 22$
										(1.09 to 1.52)	LOW
ICU Mor	tality										
CS (1)	not seri	ous	not serious	not serious	not serious	none	309	151	158	RR 1.34	$\oplus \oplus 22$
										(1.14 to 1.58)	LOW
Hospital	Mortalit y										
CS (1)	not seri	ous	not serious	not serious	not serious	none	309	151	158	RR 1.33	$\oplus \oplus 22$
										(1.14 to 1.56)	LOW
Virus clea	arance										
CS (1)	not seri	ous	not serious	not serious	not serious	none	203	99	104	RR 1.15	$\oplus \oplus 22$
										(0.77 to 1.72)	LOW
Length of	f hospital	stay									
CS (1)	not seri	ous	not serious	not serious	serious3	none	203	99	104	WMD 6.30	⊕222
										(2.36 to	VERY LOW
										10.24)	

CS: Cohort study.

Explanations

1. downgrade one level: Heterogeneity of data synthesis results,  $I^2 > 50\%$ .

2. downgrade one level: The risk of bias is high due to the limitations of study design.

3. downgrade one level: Sample size is less than optimal information sample (OIS).

4. upgrade one level: Large magnitude of effect, RR>2.




Figure 1 PRISMA flow chart

33





Figure 2 Relative risk of death in patients receiving versus not receiving glucocorticoid therapy: all patients



# Figure 3 Relative risk of death in patients receiving versus not receiving glucocorticoid therapy: subgroup analyses of patients with mild and severe SARS




Figure 4 Relative risk of death in patients receiving versus not receiving glucocorticoid therapy: subgroup analyses of adult patients with SARS




Figure 5 Duration of fever in patients receiving versus not receiving glucocorticoid therapy: all patients




Figure 6 Duration of fever in patients receiving versus not receiving glucocorticoid therapy: subgroup analyses of patients with mild and severe SARS






Figure 7 Lung inflammation absorption time in patients receiving versus not receiving glucocorticoid therapy: all patients




Figure 8 Lung inflammation absorption time in patients receiving versus not receiving glucocorticoid therapy: subgroup analyses of patients with mild and severe SARS



Study			N, mean	N, mean	%
ID		WMD (95% CI)	(SD); Treatment	(SD); Control	Weight
SARS					
Meng 2003	*	0.20 (-3.75, 4.15)	59, 16.9 (6.8)	11, 16.7 (6)	30.30
Wang 2005		8.00 (5.50, 10.50)	192, 30 (11)	49, 22 (7)	33.63
Ma 2008		11.30 (10.58, 12.0	2)3612, 31.7 (15.1)	1275, 20.4 (9.6	6)36.07
Subtotal (I-squared = 94.2%, p = 0.000)		6.83 (1.48, 12.17)	3863	1335	100.00
MERS					
Arabi 2018		6.30 (2.36, 10.24)	151, 24 (18.7)	158, 17.7 (16.5	5)100.00
Subtotal (I-squared = .%, p = .)	$\langle \rangle$	6.30 (2.36, 10.24)	151	158	100.00
COVID-19					
Shang 2020		2.00 (0.67, 3.33)	76, 12.3 (5.3)	150, 10.3 (3.7)	57.07
Shang 2020		3.00 (1.47, 4.53)	77, 14 (6)	62, 11 (3)	42.93
Subtotal (I-squared = 0.0%, p = 0.334)	$\diamond$	2.43 (1.42, 3.43)	153	212	100.00
NOTE: Weights are from random effects analysis					
-12.2	1 I 0 12				

Figure 9 Length of stay in patients receiving versus not receiving glucocorticoid therapy: all patients

Study ID	RR (95% CI)	Events, Treatment	Events, Control	% Weigł
Infection				
He 2003	2.16 (0.94, 4.96)	18/57	6/41	12.71
Meng 2003	1.40 (0.08, 25.38)	3/59	0/11	4.39
Peng 2004	10.34 (0.57, 187.08)		0/53	4.40
Ma 2008	4.15 (2.54, 6.79)	200/3612	17/1275	
Subtotal (I-squared = 0.0%, p = 0.427)	3.52 (2.33, 5.32)	225/3774	23/1380	35.79
MODS				
Ma 2008	3.85 (2.14, 6.94)	131/3612	12/1275	
Subtotal (I-squared = .%, p = .)	3.85 (2.14, 6.94)	131/3612	12/1275	13.89
DIC				
Ma 2008	9.54 (0.57, 160.29)	13/3612	0/1275	4.56
Subtotal (I-squared = .%, p = .)	9.54 (0.57, 160.29)	13/3612	0/1275	4.56
ARDS				
Ma 2008	6.07 (3.22, 11.45)	172/3612	10/1275	13.68
Subtotal (I-squared = .%, p = .)	6.07 (3.22, 11.45)	172/3612	10/1275	13.68
Hypokalemia				
He 2003	2.16 (0.94, 4.96)	18/57	6/41	12.71
Subtotal (I-squared = .%, p = .)	2.16 (0.94, 4.96)	18/57	6/41	12.71
. I Hypocalcemia I				
He 2003 🔶	1.07 (0.81, 1.41)	40/57	27/41	14.97
Subtotal (I-squared = .%, p = .)	1.07 (0.81, 1.41)	40/57	27/41	14.97
ONFH (Osteonecrosis of the Femeral Head)				
Shen 2006	3.62 (0.20, 65.75)	4/106	0/42	4.39
Subtotal (I-squared = .%, p = .)	3.62 (0.20, 65.75)	4/106	0/42	4.39
Overall (I-squared = 87.1%, p = 0.000)	3.06 (1.49, 6.29)	603/14830	78/5329	100.0
NOTE: Weights are from random effects analysis				
.00535 1	1 187			

Figure 10 Relative risk of adverse events in patients receiving versus not receiving glucocorticoid therapy




Figure 11 Sensitivity analysis of mortality in SARS patients




Figure 12 Publication bias (Egger test)

39

# Supplementary material

# Supplementary Material 1-Search strategy PubMed

- #1. "COVID-19"[Supplementary Concept]
- #2. "Severe Acute Respiratory Syndrome Coronavirus 2"[Supplementary Concept]
- #3. "Middle East Respiratory Syndrome Coronavirus"[Mesh]
- #4. "Severe Acute Respiratory Syndrome" [Mesh]
- #5. "SARS Virus"[Mesh]
- #6. "COVID-19"[Title/Abstract]
- #7. "SARS-COV-2"[Title/Abstract]
- #8. "Novel coronavirus" [Title/Abstract]
- #9. "2019-novel coronavirus" [Title/Abstract]
- #10."coronavirus disease-19" [Title/Abstract]
- #11."coronavirus disease 2019" [Title/Abstract]
- #12."COVID 19" [Title/Abstract]
- #13."Novel CoV" [Title/Abstract]
- #14."2019-nCoV" [Title/Abstract]
- #15."2019-CoV" [Title/Abstract]
- #16."Wuhan-Cov" [Title/Abstract]
- #17."Wuhan Coronavirus" [Title/Abstract]
- #18."Wuhan seafood market pneumonia virus" [Title/Abstract]
- #19."Middle East Respiratory Syndrome" [Title/Abstract]
- #20."MERS" [Title/Abstract]
- #21."MERS-CoV" [Title/Abstract]
- #22."Severe Acute Respiratory Syndrome" [Title/Abstract]
- #23."SARS" [Title/Abstract]
- #24."SARS-CoV" [Title/Abstract]
- #25."SARS-Related" [Title/Abstract]
- #26."SARS-Associated" [Title/Abstract]
- #27.#1-#26/ OR
- #28."adrenal cortex hormones"[Mesh]
- #29."Beclomethasone" [Title/Abstract]
- #30." betamethasone valerate "[Mesh]
- #31."Budesonid"[Title/Abstract]
- #32."Cortodoxone"[Title/Abstract]
- #33."Dexamethasone"[Title/Abstract]
- #34." glucocorticoids"[ Mesh]
- #35."Hydrocortisone"[Title/Abstract]
- #36."Hydroxycorticosteroids"[Title/Abstract]
- #37." methylprednisolone"[ Mesh]
- #38."adrenal cortex hormone\*"[Title/Abstract]
- #39."becl?met\*"[Title/Abstract]

40

#40."betamet?asone\*"[Title/Abstract] #41."budesonide\*"[Title/Abstract] #42."clobetasol\* "[Title/Abstract] #43."corticoid\*"[Title/Abstract] #44."corticosteroid\*"[Title/Abstract] #45."corticosterone\* "[Title/Abstract] #46."cortisone\*"[Title/Abstract] #47."cortodoxone\*"[Title/Abstract] #48."dexamet?asone\*"[Title/Abstract] #49."glucocortico\*"[Title/Abstract] #50."hydrocortisone\*"[Title/Abstract] #51."hydroxycorticosteroid\*"[Title/Abstract] #52."hydroxypregnenolone\* "[Title/Abstract] #53."methylprednisolone\*"[Title/Abstract] #54."prednisolone\*"[Title/Abstract] #55."prednisone\*"[Title/Abstract] #56."pregnenedione\*"[Title/Abstract] #57."pregnenolone\*"[Title/Abstract] #58."tetrahydrocortisol\*"[Title/Abstract] #59."triamcinolone\*"[Title/Abstract] #60.#28-#59/ OR #61.#27 AND #60

### **EMBASE**

#1. 'middle east respiratory syndrome coronavirus'/exp

- #2. 'severe acute respiratory syndrome'/exp
- #3. 'sars coronavirus'/exp
- #4. 'COVID-19':ab,ti
- #5. 'SARS-COV-2':ab,ti
- #6. 'novel coronavirus':ab,ti
- #7. '2019-novel coronavirus':ab,ti
- #8. 'coronavirus disease-19':ab,ti
- #9. 'coronavirus disease 2019':ab,ti
- #10.'COVID 19':ab,ti
- #11.'novel cov':ab,ti
- #12.'2019-ncov':ab,ti
- #13.'2019-cov':ab,ti
- #14.'wuhan-cov':ab,ti
- #15.'wuhan coronavirus':ab,ti
- #16.'wuhan seafood market pneumonia virus':ab,ti
- #17.'middle east respiratory syndrome':ab,ti
- #18.'middle east respiratory syndrome coronavirus':ab,ti

#19.'mers':ab,ti

41

#20.'mers-cov':ab,ti #21.'severe acute respiratory syndrome':ab,ti #22.'sars':ab.ti #23.'sars-cov':ab,ti #24.'sars-related':ab,ti #25.'sars-associated':ab.ti #26.#1-#25/ OR #27.'glucocorticoid'/exp #28.'methylprednisolone'/exp #29.'cortisone'/exp #30.'dexamethasone'/exp #31.'prednisone'/exp #32.'betamethasone'/exp #33.'glucocorticoid\*':ab,ti #34.'methylprednisolone\*':ab,ti #35.'cortisone\*':ab,ti #36.'dexamethasone\*':ab,ti #37.'prednisone\*':ab,ti #38.'budesonid\*':ab,ti #39.'hexadecadrol':ab.ti #40.'cortodoxone':ab,ti #41.'hydrocortisone':ab,ti #42.'hydroxycorticosteroids':ab,ti #43.'adrenal cortex hormone\*':ab.ti #44.'becl?met\*':ab,ti #45.'betamet?asone\*':ab,ti #46.'clobetasol\*':ab,ti #47.'corticoid\*':ab,ti #48.'corticosteroid\*':ab,ti #49.'corticosterone\*':ab.ti #50.'cortodoxone\*':ab,ti #51.'dexamet?asone\*':ab,ti #52.'glucocortico\*':ab,ti #53.'hydrocortisone\*':ab,ti #54.'hydroxycorticosteroid\*':ab,ti #55.'hydroxypregnenolone\*':ab,ti #56.'prednisolone\*':ab,ti #57.'pregnenedione\*':ab,ti #58.'pregnenolone\*':ab,ti #59.'tetrahydrocortisol\*':ab,ti #60.'triamcinolone\*':ab,ti #61.#27-#60/ OR #62.#25 AND #61

42

#63.#62 lim(embase)

# Cochrane

- #1. MeSH descriptor: (Middle East Respiratory Syndrome Coronavirus) explode all trees
- #2. MeSH descriptor: (Severe Acute Respiratory Syndrome) explode all trees
- #3. MeSH descriptor: (SARS Virus) explode all trees
- #4. "COVID-19":ti,ab,kw
- #5. "SARS-COV-2":ti,ab,kw
- #6. "Novel coronavirus":ti,ab,kw
- #7. "2019-novel coronavirus" :ti,ab,kw
- #8. "Novel CoV" :ti,ab,kw
- #9. "2019-nCoV" :ti,ab,kw
- #10."2019-CoV" :ti,ab,kw
- #11."coronavirus disease-19" :ti,ab,kw
- #12."coronavirus disease 2019" :ti,ab,kw
- #13."COVID 19" :ti,ab,kw
- #14."Wuhan-Cov" :ti,ab,kw
- #15."Wuhan Coronavirus" :ti,ab,kw
- #16."Wuhan seafood market pneumonia virus" :ti,ab,kw
- #17."Middle East Respiratory Syndrome" :ti,ab,kw
- #18."MERS":ti,ab,kw
- #19."MERS-CoV":ti,ab,kw
- #20."Severe Acute Respiratory Syndrome":ti,ab,kw
- #21."SARS" :ti,ab,kw
- #22."SARS-CoV" :ti,ab,kw
- #23."SARS-Related":ti,ab,kw
- #24."SARS-Associated":ti,ab,kw
- #25.#1-#24/ OR
- #26.MeSH descriptor: (Glucocorticoids) explode all trees
- #27.MeSH descriptor: (Methylprednisolone) explode all trees
- #28.MeSH descriptor: (Cortisone) explode all trees
- #29.MeSH descriptor: (Dexamethasone) explode all trees
- #30.MeSH descriptor: (Prednisone) explode all trees
- #31.MeSH descriptor: (Budesonide) explode all trees
- #32.MeSH descriptor: (Betamethasone) explode all trees
- #33. "Adrenal Cortex Hormones" : ti,ab,kw
- #34."Glucocorticoid\*" :ti,ab,kw
- #35."methylprednisolone\*" :ti,ab,kw
- #36."cortisone\*": :ti,ab,kw
- #37."Dexamethasone\*": :ti,ab,kw
- #38."prednisone\*" :ti,ab,kw
- #39."budesonid\*" :ti.ab.kw
- #40."Beclomethasone" :ti,ab,kw

43

#41."hexadecadrol" :ti,ab,kw #42."adrenal cortex hormone\*" :ti,ab,kw #43."becl?met\*" :ti,ab,kw #44."betamet?asone\*":ti,ab,kw #45."clobetasol\*": :ti,ab,kw #46."corticoid\*" :ti,ab,kw #47."corticosteroid\*": ti,ab,kw #48."corticosterone\*" :ti,ab,kw #49."cortodoxone\*" :ti,ab,kw #50."dexamet?asone\*" :ti,ab,kw #51."glucocortico\*" :ti,ab,kw #52."hydrocortisone\*": ti,ab,kw #53."hydroxycorticosteroid\*" :ti,ab,kw #54."hydroxypregnenolone\*" :ti,ab,kw #55."prednisolone\*" :ti,ab,kw #56."pregnenedione\*" :ti,ab,kw #57."pregnenolone\*" :ti,ab,kw #58."tetrahydrocortisol\*" :ti,ab,kw #59."triamcinolone\*": :ti,ab,kw #60.#26-#59/ OR #61.#25 AND #60

#### Web of Science

- #1 TOPIC: "COVID-19"
- #2 TOPIC: "SARS-COV-2"
- #3 TOPIC: "Novel coronavirus"
- #4 TOPIC: "2019-novel coronavirus"
- #5 TOPIC: "coronavirus disease-19"
- #6 TOPIC: "coronavirus disease 2019"
- #7 TOPIC: "COVID 19"
- #8 TOPIC: "Novel CoV"
- #9 TOPIC: "2019-nCoV"
- #10 TOPIC: "2019-CoV"
- #11 TOPIC: "Wuhan-Cov"
- #12 TOPIC: "Wuhan Coronavirus"
- #13 TOPIC: "Wuhan seafood market pneumonia virus"
- #14 TOPIC: "Middle East Respiratory Syndrome"
- #15 TOPIC: "MERS"
- #16 TOPIC: "MERS-CoV"
- #17 TOPIC: "Severe Acute Respiratory Syndrome"
- #18 TOPIC: "SARS"
- #19 TOPIC: "SARS-CoV"
- #20 TOPIC: "SARS-Related"

44

- #21 TOPIC: "SARS-Associated"
- #22 #1-#21/OR
- #23 TOPIC: "methylprednisolone\*"
- #24 TOPIC: "cortisone\*"
- #25 TOPIC:"Dexamethasone\*"
- #26 TOPIC: "prednisone\*"
- #27 TOPIC: "budesonid\*"
- #28 TOPIC: "Beclomethasone"
- #29 TOPIC: "hexadecadrol\*"
- #30 TOPIC: "adrenal cortex hormone\*"
- #31 TOPIC: "becl?met\*"
- #32 TOPIC: "betamet?asone\*"
- #33 TOPIC: "clobetasol\*"
- #34 TOPIC: "corticoid\*"
- #35 TOPIC: "corticosteroid\*"
- #36 TOPIC: "corticosterone\*"
- #37 TOPIC: "cortodoxone\*"
- #38 TOPIC: "dexamet?asone\*"
- #39 TOPIC: "glucocortico\*"
- #40 TOPIC: "hydrocortisone\*"
- #41 TOPIC: "hydroxycorticosteroid\*"
- #42 TOPIC: "hydroxypregnenolone\*"
- #43 TOPIC: "prednisolone\*"
- #44 TOPIC:"pregnenedione\*"
- #45 TOPIC:"pregnenolone\*"
- #46 TOPIC: "tetrahydrocortisol\*"
- #47 TOPIC: "triamcinolone\*"
- #48 #23-#47 OR
- #49 #22 AND #48

#### CBM

#1. "新型冠状病毒"(常用字段:智能)

#2. "COVID-19"(常用字段:智能)

- #3. "COVID 19"(常用字段:智能)
- #4. "2019-nCoV"(常用字段:智能)

#5. "2019-CoV"(常用字段:智能)

#6. "SARS-CoV-2"(常用字段:智能)

45

#7. "武汉冠状病毒"(常用字段:智能)

#8. "中东呼吸综合征冠状病毒"(不加权:扩展)

#9. "中东呼吸综合征"(常用字段:智能)

#10."MERS"(常用字段:智能)

#11."MERS-CoV"(常用字段:智能)

#12."严重急性呼吸综合征"(不加权:扩展)

#13."SARS 病毒"(不加权:扩展)

#14."严重急性呼吸综合征"(常用字段:智能)

#15."SARS"(常用字段:智能)

#16.#1-#15/ OR

#17."糖皮质激素"(不加权:扩展)

#18."糖皮质激素"(常用字段:智能)

#19."可的松"(常用字段:智能)

#20."布地奈德"(常用字段:智能)

#21."地塞米松"(常用字段:智能)

#22."强的松"(常用字段:智能)

#23."泼尼松"(常用字段:智能)

#24."甲泼尼龙"(常用字段:智能)

#25."甲强龙"(常用字段:智能)

#26.#17-#25/ OR

#27.#16 AND #26

#### WanFang

#1. "新型冠状病毒"(主题)

46

- #2. "COVID-19"(主题)
- #3. "COVID 19"(主题)
- #4. "2019-nCoV"(主题)
- #5. "2019-CoV"(主题)
- #6. "SARS-CoV-2"(主题)
- #7. "武汉冠状病毒"(主题)
- #8. "中东呼吸综合征"(主题)
- #9. "MERS"(主题)
- #10."MERS-CoV"(主题)
- #11."严重急性呼吸综合征"(主题)
- #12."SARS"(主题)
- #13.#1-#12/ OR
- #14."糖皮质激素"(主题)
- #15."泼尼松"(主题)
- #16."强的松"(主题)
- #17."布地奈德"(主题)
- #18."地塞米松"(主题)
- #19."可的松"(主题)
- #20."甲泼尼龙"(主题)
- #21."甲强龙"(主题)
- #22.#14-#21/ OR #23.#13 AND #22

# CNKI

- #1. "新型冠状病毒"(主题)
- #2. "COVID-19"(主题)
- #3. "COVID 19"(主题)
- #4. "2019-nCoV"(主题)
- #5. "2019-CoV"(主题)
- #6. "SARS-CoV-2"(主题)
- #7. "武汉冠状病毒"(主题)
- #8. "中东呼吸综合征"(主题)
- #9. "MERS"(主题)
- #10."MERS-CoV"(主题)
- #11."严重急性呼吸综合征"(主题)
- #12."SARS"(主题)
- #13.#1-#12/ OR
- #14."糖皮质激素"(主题)
- #15."泼尼松"(主题)
- #16."强的松"(主题)
- #17."布地奈德"(主题)
- #18."地塞米松"(主题)
- #19."可的松"(主题)
- #20."甲泼尼龙"(主题)
- #21."甲强龙"(主题)
- #22.#14-#21/ OR
- #23.#13 AND #22